93962-66-4

Usage

Chemical structure

1-(3-bromopropyl)-2,4-dichlorobenzene is composed of a benzene ring with two chlorine atoms at the 2 and 4 positions, and a bromine atom attached to a propyl chain at the 1 position.

Industrial applications

It is used in the production of pesticides, flame retardants, and as an intermediate in the synthesis of other organic compounds.

Potential hazards

The presence of bromine and chlorine atoms makes it a potentially hazardous chemical.

Safety guidelines

It is important to handle it with care and follow safety guidelines during its use and storage.

Environmental and human safety

It is important to be aware of any regulations and restrictions related to the handling and disposal of this chemical to ensure environmental and human safety.

InChI:InChI=1/C9H9BrCl2/c10-5-1-2-7-3-4-8(11)6-9(7)12/h3-4,6H,1-2,5H2

Upstream product

• 874-42-0 2,4-dichlorobenzaldeyhde 
• 42174-01-6 methyl 2,4-dichlorocinnamate 
• 1504-59-2 3-(2.4-Dichlor-phenyl)-prop-2-en-1-ol 
• 20595-45-3 2,4-dichlorocinnamic acid 
• 146882-07-7 3-(2,4-dichlorophenyl)propan-1-ol 

Downstream Products

• 1026334-46-2 Thioacetic acid S-[3-(2,4-dichloro-phenyl)-propyl] ester 
• 1355026-30-0 C₁₅H₁₄Cl₂N₂O₃ 
• 1027496-33-8 3-Cyano-4-[3-(2,4-dichloro-phenyl)-propylsulfanyl]-3-hydroxy-butyric acid methyl ester 
• 1026639-62-2 4-[3-(2,4-Dichloro-phenyl)-propylsulfanyl]-3-oxo-butyric acid methyl ester 

Relevant academic research and scientific papers

Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists

High affinity and selective small molecule agonists of the S1P4 receptor (S1P4-R) may have significant therapeutic utility in diverse disease areas including autoimmune diseases, viral infections and thrombocytopenia. A high-throughput screening (HTS) of the Molecular Libraries-Small Molecule Repository library identified 3-(2-(2,4- dichlorophenoxy)ethoxy)-6-methyl-2-nitropyridine as a moderately potent and selective S1P4-R hit agonist. Design, synthesis and systematic structure-activity relationships study of the HTS-derived hit led to the development of novel potent S1P4-R agonists exquisitely selective over the remaining S1P1-3,5-Rs family members. Remarkably, the molecules herein reported provide novel pharmacological tools to decipher the biological function and assess the therapeutic utility of the S1P4-R.

ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme

ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of 2-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme. The best compounds, 58, 68, 71, 74 have reversible K(i)'s in the 1-3 μM range against the isolated rat enzyme. As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP- citrate lyase.